Key result
Recombinant hirudin successfully provides alternative anticoagulation during CPB for a patient with HIT.
Why the study?
Does r-Hirudin provide safe and effective anticoagulation during cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia?
Case Report (n=1)
No
Does r-Hirudin provide safe and effective anticoagulation during cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia?
r-Hirudin can be successfully used as an alternative anticoagulant for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia, though careful monitoring of coagulation parameters is required.
Supports r-hirudin feasibility in HIT during CPB; hypothesis-generating and requires prospective validation.
Heparin-induced thrombocytopenia and its related complications can be life-threatening in patients undergoing cardiopulmonary bypass (CPB) with heparin exposure. While the literature illustrates many different techniques which might be employed in this situation, most are used infrequently. This case report provides an overview of the successful use of r-Hirudin, and associated monitoring techniques, in a high-risk patient undergoing cardiac surgery utilizing CPB.
No takes yet. Share an insight, caveat, or question.
David P. Webb (2000) conducted a case report in Heparin-induced thrombocytopenia (HIT) requiring cardiopulmonary bypass (n=1). r-Hirudin was evaluated on Successful completion of cardiopulmonary bypass without complications. Recombinant hirudin (r-Hirudin) was successfully used as an alternative anticoagulant to heparin in a 56-year-old male with heparin-induced thrombocytopenia undergoing cardiopulmonary bypass.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: